The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Brent M. Egan

Department of Medicine

Division of General Internal Medicine

Medical University of South Carolina

Charleston 29425

USA

[email]@musc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medicine, Division of General Internal Medicine, Medical University of South Carolina, Charleston 29425, USA. 2003 - 2012
  • Medical University of South Carolina, 135 Rutledge Ave, RT1230, Charleston. 1998 - 2012

References

  1. Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice. Egan, B.M., Shaftman, S.R., Wagner, C.S., Bandyopadhyay, D., Szymanski, K.A. Ethn. Dis (2012) [Pubmed]
  2. Initial monotherapy and combination therapy and hypertension control the first year. Egan, B.M., Bandyopadhyay, D., Shaftman, S.R., Wagner, C.S., Zhao, Y., Yu-Isenberg, K.S. Hypertension (2012) [Pubmed]
  3. Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea. Egan, B.M. Hypertension (2011) [Pubmed]
  4. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Egan, B.M., Zhao, Y., Axon, R.N., Brzezinski, W.A., Ferdinand, K.C. Circulation (2011) [Pubmed]
  5. Prehypertension: an opportunity for a new public health paradigm. Egan, B.M., Lackland, D.T., Jones, D.W. Cardiol. Clin (2010) [Pubmed]
  6. Does dark chocolate have a role in the prevention and management of hypertension?: commentary on the evidence. Egan, B.M., Laken, M.A., Donovan, J.L., Woolson, R.F. Hypertension (2010) [Pubmed]
  7. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. Egan, B.M., Zhao, Y., Axon, R.N. JAMA (2010) [Pubmed]
  8. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Egan, B.M., Basile, J.N., Rehman, S.U., Davis, P.B., Grob, C.H., Riehle, J.F., Walters, C.A., Lackland, D.T., Merali, C., Sealey, J.E., Laragh, J.H. Am. J. Hypertens. (2009) [Pubmed]
  9. Prehypertension: should we be treating with pharmacologic therapy? Egan, B.M., Nesbitt, S.D., Julius, S. Ther. Adv. Cardiovasc. Dis (2008) [Pubmed]
  10. Prehypertension: risk stratification and management considerations. Egan, B.M., Julius, S. Curr. Hypertens. Rep. (2008) [Pubmed]
  11. Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. Egan, B.M. J. Clin. Hypertens. (Greenwich) (2007) [Pubmed]
  12. Challenges and risks in attaining the systolic blood pressure goal of <130 mm Hg in all diabetic patients. Egan, B.M. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  13. Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. Egan, B.M., Lackland, D.T., Igho-Pemu, P., Hendrix, K.H., Basile, J., Rehman, S.U., Okonofua, E.C., Quarshie, A., Oduwole, A., Onwuanyi, A., Reed, J., Obialo, C., Ofili, E.O. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  14. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Egan, B.M., Papademetriou, V., Wofford, M., Calhoun, D., Fernandes, J., Riehle, J.E., Nesbitt, S., Michelson, E., Julius, S. Am. J. Hypertens. (2005) [Pubmed]
  15. Cardioprotection: the role of beta-blocker therapy. Egan, B.M., Basile, J., Chilton, R.J., Cohen, J.D. J. Clin. Hypertens. (Greenwich) (2005) [Pubmed]
  16. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Egan, B., Gleim, G., Panish, J. Curr. Med. Res. Opin (2004) [Pubmed]
  17. Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. Egan, B.M., Lackland, D.T., Cutler, N.E. Arch. Intern. Med. (2003) [Pubmed]
  18. Insulin resistance and the sympathetic nervous system. Egan, B.M. Curr. Hypertens. Rep. (2003) [Pubmed]
  19. Controlling blood pressure in 50% of all hypertensive patients: an achievable goal in the healthy people 2010 report?. Egan, B.M., Basile, J.N. J. Investig. Med. (2003) [Pubmed]
  20. Beta-blockers for cardioprotection. A forgotten message?. Egan, B.M. Postgrad. Med (2003) [Pubmed]
  21. Other important applications for beta-blockers in high-risk patients. Egan, B.M., Chilton, R.J. Postgrad. Med (2003) [Pubmed]
  22. American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. Egan, B.M., Lackland, D.T., Basile, J.N. Am. J. Hypertens. (2002) [Pubmed]
  23. Nonesterified fatty acids in blood pressure control and cardiovascular complications. Egan, B.M., Greene, E.L., Goodfriend, T.L. Curr. Hypertens. Rep. (2001) [Pubmed]
  24. Insulin resistance and cardiovascular disease. Egan, B.M., Greene, E.L., Goodfriend, T.L. Am. J. Hypertens. (2001) [Pubmed]
  25. Health care improvement and cost reduction opportunities in hypertensive Medicaid beneficiaries. Egan, B.M., Lackland, D.T., Williams, B., Gunter, N., Tocharoen, A., Beardon, L. J. Clin. Hypertens. (Greenwich) (2001) [Pubmed]
  26. Biochemical and metabolic effects of very-low-salt diets. Egan, B.M., Lackland, D.T. Am. J. Med. Sci. (2000) [Pubmed]
  27. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Egan, B.M., Lu, G., Greene, E.L. Prostaglandins Leukot. Essent. Fatty Acids (1999) [Pubmed]
  28. Strategies for cardiovascular disease prevention: importance of public and community health programs. Egan, B.M., Lackland, D.T. Ethn. Dis (1998) [Pubmed]
 
WikiGenes - Universities